Meritage Portfolio Management Sells 90 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Meritage Portfolio Management decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 661 shares of the medical equipment provider’s stock after selling 90 shares during the quarter. Meritage Portfolio Management’s holdings in Intuitive Surgical were worth $223,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Portside Wealth Group LLC boosted its holdings in shares of Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after acquiring an additional 3,054 shares during the period. Kades & Cheifetz LLC bought a new position in shares of Intuitive Surgical in the 4th quarter valued at about $230,000. Blair William & Co. IL increased its stake in shares of Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Myriam Curet sold 5,318 shares of the stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at $110,456.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Over the last three months, insiders sold 249,418 shares of company stock worth $96,300,959. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Trading Up 0.6 %

Shares of Intuitive Surgical stock opened at $375.33 on Friday. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The firm has a market capitalization of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.36. The firm’s 50 day moving average is $386.19 and its 200 day moving average is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.00 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on ISRG. Raymond James lifted their target price on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Jefferies Financial Group raised their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Truist Financial increased their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Piper Sandler upped their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Finally, BTIG Research increased their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.